Oruka Therapeutics Inc. (ORKA) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Oruka Therapeutics Inc. (ORKA) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How ORKA Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $4.00B | 0% | -3.1% | -$105.4M | -$88.4M | -22.3% |
| FY 2024 | $4.00B | 0% | -2.2% | -$83.7M | -$58.0M | -21.3% |
| FY 2023 | $4.00B | 0% | -0.2% | -$5.3M | -$5.0M | -0.3% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring ORKA)
- ✓Live walkthrough of ORKA's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
ORKA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -4.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on ORKA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for ORKA. Explore sector supply chains on /butterfly.
ORKA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Oruka Therapeutics Inc. (ORKA)?
In FY 2025 (10-K), ORKA converted $4.0B of revenue into a 0% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).